ETA versus mAb (reference = mAb) | |||||
---|---|---|---|---|---|
Qualitative analysis | Quantitative analysis | ||||
OR [95% CI] | p | RR [95% CI] | p | ||
First year of TNF inhibitor treatment | Unadjusted for PS | 0.81 [0.32, 2.03] | 0.65 | 0.54 [0.24, 1.24] | 0.15 |
Adjusted for PS | 0.94 [0.35, 2.54] | 0.90 | 0.62 [0.26, 1.46] | 0.27 | |
First-line TNF inhibitor | Unadjusted for PS* | 1.39 [0.71, 2.72] | 0.30 | 0.97 [0.66, 1.43] | 0.89 |
Adjusted for PS* | 1.89 [0.90, 4.01] | 0.09 | 1.10 [0.70, 1.72] | 0.68 | |
All therapeutic lines of TNF inhibitors | Unadjusted for PS* | 1.57 [0.71, 3.46] | 0.27 | 1.01 [0.61; 1.69] | 0.96 |
Adjusted for PS* | 1.98 [0.90, 4.37] | 0.08 | 1.21 [0.68, 2.16] | 0.53 |